GW Medical Technologies, LLC Announces Study Team For Its Phase II Alzheimer’s Blood Diagnostic Test

PHOENIX--(BUSINESS WIRE)--GW Medical Technologies LLC was recently awarded a $1,036,000 Phase II SBIR Grant from the National Institute on Aging, a division of the National Institutes of Health. The grant will assist GW Medical to further develop, refine and commercialize its new LymPro Test®, a blood diagnostic test for early detection of Alzheimer’s disease (AD).

MORE ON THIS TOPIC